PXD021792 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | Proteomics and phosphoproteomics on NB1 and IMR32 neuroblastoma cells stimulated with ALAKAL2 |
Description | High-risk neuroblastoma (NB) is notoriously difficult to treat and is responsible for a disproportionate number of childhood deaths due to cancer. One long accepted indicator of high-risk NB and poor prognosis is amplification of the neural MYC (MYCN) oncogene, which is currently therapeutically intractable in this patient population. The identification of Anaplastic Lymphoma Kinase (ALK) as an oncogene in NB raised the possibility of using ALK tyrosine kinase inhibitors (TKIs) in the treatment of NB patients who harbor activating ALK mutations. The number of ALK-positive NB patients on primary diagnosis is in the range of 8-10%, a figure that increases substantially in the relapsed patient population. ALK signaling is activated by the ALKAL2 ligand located on the distal portion of chromosome 2, along with the ALK receptor and MYCN loci, in the ‘2p gain’ region that has been associated with NB. The question of whether dysregulation of ALK ligand may also play a role in NB has not been addressed, although notably, one of the first oncogenes described was the v-sis oncogene that shares more than 90% homology with the PDGF ligand. Therefore, we tested whether ALKAL ligand was able to potentiate NB progression in the absence of ALK mutation. We show here that overexpression of ALKAL2 is sufficient to drive rapid onset and penetrant Th-MYCN driven NB in the absence of ALK mutation, and that these tumours are sensitive to ALK TKI therapy. These results suggest that additional NB patients, such as those exhibiting 2p gain, may also benefit from ALK TKI based therapeutic intervention. |
HostingRepository | PRIDE |
AnnounceDate | 2020-11-25 |
AnnouncementXML | Submission_2020-11-24_22:25:44.xml |
DigitalObjectIdentifier | |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Unsupported dataset by repository |
PrimarySubmitter | Proteomics Core Facility |
SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
ModificationList | TMT6plex-126 reporter+balance reagent acylated residue; methylthiolated residue |
Instrument | Orbitrap Fusion Lumos |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2020-10-02 04:16:40 | ID requested | |
⏵ 1 | 2020-11-24 22:25:44 | announced | |
Publication List
Dataset with its publication pending |
Keyword List
submitter keyword: ALKAL2, neuroblastoma, NB, cancer, Anaplastic Lymphoma Kinase, ALK, tandem mass tag, TMT, phosphorylation |
Contact List
Ruth H. Palmer |
contact affiliation | Professor, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden |
contact email | ruth.palmer@gu.se |
lab head | |
Proteomics Core Facility |
contact affiliation | SAMBIO Core Facilities, Sahgrenska Academy, University of Gothenburg |
contact email | gupcf@outlook.com |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2020/11/PXD021792 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD021792
- Label: PRIDE project
- Name: Proteomics and phosphoproteomics on NB1 and IMR32 neuroblastoma cells stimulated with ALAKAL2